A Zapyrus Original Series: Building a Go-to-Market Strategy that Scales with ILIKOS Consulting Group

Successful business development that scales in the MedTech space takes more than a strong service offering—it requires precision, timing, and the ability to translate sales signals into meaningful business development action. Yet many MedTech service providers still rely on outdated, volume-driven outreach strategies that waste time and miss the real opportunities.

As highlighted in a recent discussion with ILIKOS Consulting Group, the gap is clear: MedTech service providers need to grow their pipeline, but most don’t know how to leverage tools effectively to build a truly scalable and effective go-to-market (GTM) strategy.

In the words of Elias Sayias, founder of ILIKOS Consulting Group, “Zapyrus is not just a software that you're getting. You're getting a sales partnership solution that gives you the necessary market indicators and knowledge–combined with the right timing–to conduct targeted outreach in the most effective manner.” 

While sales and marketing tools can be additive, technology alone is not a strategy. The technology is only able to support your commercial team if they understand the information available and know how to leverage it in a way that drives your business objectives.

Here’s what MedTech service providers need to know to build a GTM strategy that scales—and how to use market intelligence the right way.

A scalable GTM strategy starts with understanding buyer intent

Too many teams mistake “more data” for “better strategy.” But scalable growth depends on your team’s ability to interpret sales triggers and indicators to identify real-time, high-value opportunities, not pump up cold outreach and cross your fingers.

MedTech service providers that consistently and effectively scale growth understand that:

• Funding activity is only one signal [albeit a critical sales signal]
• Timing and insight matters more than volume
• Sales indicators must be interpreted together, not in isolation
• Commercial teams require training to understand how to use sales and marketing tools, and how to effectively collaborate across departments to ensure alignment

A scalable GTM engine is one where business development professionals know how to convert signals into insights—and insights into the right outreach at the right moment. Zapyrus is the only tool built specifically for MedTech service providers, giving teams real-time actionable market intelligence based on critical buying signals. Zapyrus Intelligence combines MedTech sales triggers across clinical, regulatory, financial, corporate, and partnership activity—and provides strategic insights to use the collective data to create meaningful, value-driven outreach.

The biggest mistake MedTech service providers make: relying on a single data point or sales trigger

Sayais calls out a common industry misstep: relying on a single piece of information to create one message with the expectation it will resonate across all target prospects. 

“I hear a lot of BD professionals say this: Download a list of companies in Texas that got funded three months ago, and reach out to all of them. That already is mistake number one,” says Sayias.

What not to do:

• Rely exclusively on financial milestone announcements
• Send mass outreach to every company that fits a broad filter
• Assume funding alone equals ready-to-buy
• Ignore pre-funding and post-funding triggers that signal real intent

Funding is a sales indicator, not a buying decision.

When service providers limit their GTM strategy to a single trigger, they create shallow, non-repeatable, non-scalable pipeline activity that doesn’t land.

The real magic and the biggest advantage: building a multi-signal, high-intent GTM strategy with Zapyrus

If relying on a single data point is the biggest mistake MedTech service providers make, then the solution is clear: build a GTM system that captures true commercial intent, not just noise. Funding may open a window of opportunity, but it is only one piece of a much broader picture. High-performing teams replace single-trigger outreach with a multi-dimensional, insight-driven approach.

1. Build a multi-signal trigger system
   Incorporate funding announcements with clinical, regulatory, hiring, IP, operational, and partnership activity signals. When combined, these indicators reveal where momentum is forming, where bottlenecks are likely to occur, and MedTech service providers can offer solutions to create measurable impact. Context—not just data—drives timing and relevance.
2. Prioritize accounts based on stage-specific needs
   Commercial readiness looks different at each stage of a MedTech company’s lifecycle. Align your outreach to what companies at that exact stage are typically solving for, whether that’s prototyping, clinical trial execution, manufacturing scale-up, or early commercialization. Precision targeting increases conversion and shortens sales cycles.
3. Craft persona-specific messaging
   One message will never resonate across buyer personas like R&D leaders, founders, regulatory executives, and commercial teams. Tailor your value proposition to the unique pain points and needs of each stakeholder. Personalization rooted in role, not milestones, is what drives engagement and builds trust with your audience.
4. Leverage pre-funding intent signals
   Some of the strongest indicators of readiness occur before capital hits the bank. Job postings, increases in IP activity, clinical trial expansion, and early regulatory moves often signal upcoming growth. Engaging early differentiates you from competitors who rely on intent data like keyword mentions.
5. Anchor every message in solving business challenges
   Milestones provide context, but pain points create urgency. Position your solution around solving critical challenges—risk mitigation, speed, cost, compliance, or resource constraints. When the problem is clear, the conversation becomes inevitable. Focus on the outcome, not the tactical steps it takes to get there.
6. Build a repeatable, segmented outreach strategy
   Replace broad, blast-style cold outreach with a structured GTM engine that segments companies by their stage and multiple sales signals (ie: funding activity, clinical trial updates, approaching submission, scaling manufacturing, or entering commercialization). This creates a predictable pipeline that allows your team to scale growth and more accurately assess deal close rate.
7. Time your outreach to operational inflection points
   Buying decisions cluster around moments of stress: trial expansion, manufacturing scale-up, regulatory deadlines, supply chain issues, or new site activations. Engage when the stakes are high and urgency peaks. Zapyrus is the only platform on the market that delivers real-time, MedTech-specific insights giving you this level of precision.

A Scalable MedTech GTM strategy is built on real-time, actionable insights

A scalable GTM strategy isn’t a tactic—it’s a cross-functional ecosystem that relies on alignment across your organization. Combining multi-signal intelligence, stage-based segmentation, relevant messaging, well-aligned CTAs, and timing grounded in operational needs creates durable, momentum-driven growth. This is how MedTech service providers build pipelines that refill themselves instead of relying on unpredictable bursts.